A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 25 Feb 2019
Price : $35 *
At a glance
- Drugs Temozolomide (Primary)
- Indications Astrocytoma; Oligodendroglioma
- Focus Therapeutic Use
- 20 Feb 2019 Planned End Date changed from 1 May 2016 to 1 May 2019.
- 20 Feb 2019 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2019.
- 20 Feb 2019 Status changed from recruiting to active, no longer recruiting.